AYTU Stock — Aytu BioScience Inc

Aytu BioScience Inc (AYTU)

Updated October 16, 2026.

AYTU is a Stock. Its deepest 1-year drawdown was 32.8%.

Aytu BioPharma is a pharmaceutical company that commercializes novel therapeutics in the United States and internationally, with a focus on prescription products for treating attention deficit hyperactivity disorder (ADHD) and pediatric conditions including allergies and vitamin deficiencies. The company does not currently distribute income to shareholders. This security appeals to investors seeking exposure to the pharmaceutical and healthcare sector, though it is not suitable for those dependent on dividend income.

AYTU performance

Returns are updating. AYTU's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 32.8%.

AYTU key facts

Asset type

Stock

Asset class

Equity

Inception date

09/24/2008

Distribution frequency

None

Last close

$2.04 (as of 2026-10-16)

Market cap

$22,168,084

Average volume

29948.0

Payment date

12/09/2020

Beta

0.178

Payout ratio

0.0%

Forward P/E

9.1575

EPS

$-1.16

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

AYTU risks and drawbacks

The deepest 1-year drawdown on record here is 32.8%.

Who may consider AYTU — and who may not

It is a weaker fit for investors who need monthly cash flow (AYTU does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on AYTU

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions